Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMR-001 in CALR-mutant Myeloproliferative Neoplasms
NCT07849231Phase 1Recruiting
- Sponsor
- Damora Therapeutics
- Start
- Sep 2026
- Primary completion
- Jun 2030
- Countries
- 2
01
Overview
Phase 1, open-label trial of DMR-001 in essential thrombocythemia (ET) and myelofibrosis (MF) (3 arms), sponsored by Damora Therapeutics. Primary endpoint: Safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) at 672 days. Started Sep 2026; status: recruiting.
02
Drugs
DMR-001
03
Conditions
essential thrombocythemia (ET)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07849231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849231.